老年心力衰竭患者的再诊断。回顾性研究

R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço
{"title":"老年心力衰竭患者的再诊断。回顾性研究","authors":"R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço","doi":"10.4081/GC.2020.9106","DOIUrl":null,"url":null,"abstract":"Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.","PeriodicalId":30930,"journal":{"name":"Geriatric Care","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/GC.2020.9106","citationCount":"0","resultStr":"{\"title\":\"Readmissions in elderly patients with heart failure. A retrospective study\",\"authors\":\"R. Alves, M. Fernandes, I. Figueiredo, D. Borges, Filipa Louenço\",\"doi\":\"10.4081/GC.2020.9106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.\",\"PeriodicalId\":30930,\"journal\":{\"name\":\"Geriatric Care\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/GC.2020.9106\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Geriatric Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/GC.2020.9106\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geriatric Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/GC.2020.9106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

心力衰竭是全世界发病率和死亡率的主要原因。患病率随着年龄的增长而增加,通常会恶化,导致患者反复入院,并带来严重的症状负担。对这些患者的正确治疗可以减少再次入院,提高生活质量。我们的目的是比较内科病房中有和没有1年再次入院的老年患者,特别是在死亡率方面。回顾性研究,查阅患者的临床记录,诊断为心力衰竭。将患者分为两组:一年内有(wR)和无(woR)再入院。死亡率是主要结果。89名患者被纳入;60wR和29wR。两组之间没有性别差异,wR组有年龄较大的患者。最常见的合并症包括心房颤动、高血压和慢性肾功能衰竭3期或以上。最常见的住院原因是治疗不足或疾病自然发展导致的心力衰竭。心力衰竭的病因主要是高血压和缺血性。wR组有更多的患者被分类为NYHA>III。关于主要结果;重复入院组12个月时的死亡率较高。这一人群的特征使我们能够强调失代偿的原因,并审查药物以提高生活质量。引言和目的心力衰竭被定义为一种临床综合征,包括呼吸困难、疲劳和外周水肿等典型症状,其中许多与结构或功能性心脏异常引起的充血和液体过载有关。15心力衰竭目前分为三个亚组;射血分数降低的心力衰竭(EF50%)。5根据症状严重程度和运动耐受性,使用纽约心脏学会功能分类法对心力衰竭的严重程度进行分类。心力衰竭是全世界发病率和死亡率的主要原因;它影响了约2%的成年人口,一生中患心力衰竭的风险为五分之一。1-3患病率随着年龄的增长而增加,并与高血压、冠状动脉疾病、心肌病和瓣膜病等高度流行的合并症有关。由于人口老龄化,心力衰竭的患病率预计在未来20年内将增加25%。1,3尽管情况有所改善,但死亡率仍然很高,慢性心力衰竭的发病率为6-7%,急性失代偿和住院患者的死亡率为25%。1,3,69根据欧洲指南,5 EF降低的心力衰竭治疗是基于神经激素拮抗剂和阻断心脏重塑、改善预后的装置,以及缓解充血的利尿剂。3,5神经激素拮抗药包括ACE抑制剂;血管紧张素受体阻滞剂;β受体阻滞剂;盐皮质激素受体拮抗剂;以及,根据最近的数据,血管紧张素受体阻滞剂奈普赖氨酸抑制剂(ARNI)。这些干预措施已被证明可以改善预后。5心力衰竭有复杂的相关症状,预后不确定,需要多次入院以控制失代偿发作。4心力衰竭通常会发展,而且很多时候是致命的,这给患者带来了很大的症状负担。材料和方法我们描述了一项回顾性研究,查阅了一名患者的临床记录,该患者是2017年在一家三级医院内科病房住院的65岁以上诊断为心力衰竭的医院人群。患者在里斯本。我们将人群分为1年内有(wR)和无(woR)再次入院的两组,并就患者的性别、年龄、自主性水平、合并症和住院原因进行比较。对心脏病的病因、BNP测定和超声心动图进行了表征。主要结果是12个月时死亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Readmissions in elderly patients with heart failure. A retrospective study
Heart failure is a major cause of morbidity and mortality worldwide. The prevalence increases with age and usually progresses, leading to repeated hospital admissions and significant symptom burden for patients. The correct management of these patients may decrease readmissions and increase quality of life. Our aim is to compare elderly patients with and without 1-year readmissions in an internal medicine ward, particularly in terms of mortality. Retrospective study, consulting patient’s clinical records, with a diagnosis of heart failure. The patients were characterized and divided in groups: with (wR) and without readmission (woR) within 1 year. Mortality was the primary outcome. Eighty-nine patients were included; 60 woR and 29 wR. There was no gender difference between groups, the wR group had older patients. The most frequent comorbidities included atrial fibrillation, hypertension and chronic renal failure stage 3 or higher. The most frequent cause of hospitalization was heart failure due to insufficient therapy or natural progression of the disease. The etiology of heart failure was mainly hypertensive and ischemic. The wR group had more patients classified as NYHA >III . In relation to the primary outcome; mortality at 12 months was higher in the group with repeated admissions . The characterization of this population allows us to highlight the causes of decompensation and to review medication in order to increase the quality of life. Introduction and objectives Heart failure is defined as a clinical syndrome comprised of typical symptoms including breathlessness, fatigue and peripheral edema, among others, many related to congestion and fluid overload resulting from structural or functional cardiac abnormality.15 Heart failure is currently divided in three subgroups; heart failure with decreased ejection fraction (EF) (EF<40%), heart failure with intermediate EF (EF 40-49%) which currently has no clinical implications but is a target for research, and finally heart failure with preserved EF (EF>50%).5 Heart failure severity is classified according to symptom severity and exercise tolerance using the New York Heart Academy functional classification. Heart failure is a major cause of morbidity and mortality worldwide; it affects about 2% of the adult population, and the lifetime risk of developing heart failure is one in five.1-3 The prevalence increases with age and it is associated with highly prevalent comorbidities such as hypertension, coronary artery disease, cardiomyopathies and valve disease. As a result of ageing of the population the prevalence of heart failure is projected to increase by 25% in the next 20 years.1,3 Mortality remains high despite improvements, with a rate of 6-7% in chronic heart failure and 25% in patients with acute decompensations and hospital admission.1,3,69 According to European guidelines,5 heart failure with reduced EF treatment is based on neuro-hormonal antagonists and devices to block the remodeling of the heart and improve outcomes and diuretics for relief of congestion.3,5 Neuro-hormonal antagonists include ACE inhibitors; angiotensin receptor blockers (ARBs); β blockers; mineralocorticoid receptor antagonists (MRAs); and, based on more recent data, angiotensin receptor blocker neprilysin inhibitors (ARNIs). These interventions have been shown to improve outcomes.5 Heart failure has complex symptoms associated, with uncertain prognosis, with multiple hospital admissions to control episodes of decompensation.4 Heart failure usually progresses, and is many times, a fatal condition, which provides much symptom burden for patients. Materials and Methods We describe a retrospective study, consulting a patient’s clinical records, hospital population over 65 years of age with a diagnosis of heart failure, hospitalized in the year of 2017, in an internal medicine ward in a tertiary hospital. Patients were in Lisbon. We divided the population into 2 groups with (wR) and without (woR) hospital readmission within 1 year and were compared regarding the patient’s gender, age, level of autonomy, comorbidities and reason for hospitalization. The etiology of heart disease, BNP assay and echocardiogram were characterized. The primary outcome was death at 12 months.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
15
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信